CN110585209A - 治疗瘙痒的方法 - Google Patents

治疗瘙痒的方法 Download PDF

Info

Publication number
CN110585209A
CN110585209A CN201910603708.9A CN201910603708A CN110585209A CN 110585209 A CN110585209 A CN 110585209A CN 201910603708 A CN201910603708 A CN 201910603708A CN 110585209 A CN110585209 A CN 110585209A
Authority
CN
China
Prior art keywords
day
nalbuphine
dose
sustained release
pruritus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910603708.9A
Other languages
English (en)
Chinese (zh)
Inventor
T·夏夏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trevi Therapeutics Inc
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/715,625 external-priority patent/US8637538B1/en
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of CN110585209A publication Critical patent/CN110585209A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
CN201910603708.9A 2012-12-14 2013-12-13 治疗瘙痒的方法 Pending CN110585209A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261737488P 2012-12-14 2012-12-14
US13/715,625 US8637538B1 (en) 2012-12-14 2012-12-14 Methods for treatment of pruritis
US13/715,625 2012-12-14
US61/737,488 2012-12-14
CN201380072542.3A CN104981246A (zh) 2012-12-14 2013-12-13 治疗瘙痒的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380072542.3A Division CN104981246A (zh) 2012-12-14 2013-12-13 治疗瘙痒的方法

Publications (1)

Publication Number Publication Date
CN110585209A true CN110585209A (zh) 2019-12-20

Family

ID=50935003

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910603708.9A Pending CN110585209A (zh) 2012-12-14 2013-12-13 治疗瘙痒的方法
CN201380072542.3A Pending CN104981246A (zh) 2012-12-14 2013-12-13 治疗瘙痒的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380072542.3A Pending CN104981246A (zh) 2012-12-14 2013-12-13 治疗瘙痒的方法

Country Status (13)

Country Link
EP (1) EP2931279B1 (cg-RX-API-DMAC7.html)
JP (4) JP2016506398A (cg-RX-API-DMAC7.html)
KR (3) KR20150093702A (cg-RX-API-DMAC7.html)
CN (2) CN110585209A (cg-RX-API-DMAC7.html)
AU (2) AU2013359017B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015013984A2 (cg-RX-API-DMAC7.html)
CA (1) CA2892393C (cg-RX-API-DMAC7.html)
ES (1) ES2984559T3 (cg-RX-API-DMAC7.html)
MX (1) MX2015007518A (cg-RX-API-DMAC7.html)
NZ (1) NZ708371A (cg-RX-API-DMAC7.html)
RU (1) RU2015128265A (cg-RX-API-DMAC7.html)
WO (1) WO2014093871A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201504229B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法
WO2015192071A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
TW201725041A (zh) * 2016-01-04 2017-07-16 懷特生技新藥股份有限公司 治療皮膚癢之醫藥組合物
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
CA3017374A1 (en) * 2016-03-21 2017-09-28 Trevi Therapeutics, Inc. Treatment of uremic pruritus
WO2018081273A1 (en) * 2016-10-25 2018-05-03 Trevi Therapeutics, Inc. Treatment of prurigo nodularis
KR102329377B1 (ko) * 2017-02-03 2021-11-19 가부시키가이샤 도요 신야쿠 고형 제제
CN118512451A (zh) * 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
US20090030026A1 (en) * 2005-08-24 2009-01-29 Baichwal Anand R Sustained release formulations of nalbuphine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535687A (zh) * 1996-11-25 2004-10-13 ������������ʽ���� 止痒药物
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
LT2425821T (lt) * 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
CA2566217A1 (en) * 2004-06-03 2005-12-15 Jonathan J. Burbaum Pharmaceutical compositions for the treatment of pruritus
CA2620224C (en) 2005-08-24 2015-11-24 Penwest Pharmaceuticals Company Sustained release formulations of nalbuphine
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
US20090030026A1 (en) * 2005-08-24 2009-01-29 Baichwal Anand R Sustained release formulations of nalbuphine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHARULUXANANAN SOMRAT等: "Optimal Dose of Nalbuphine for Treatment of Intrathecal-Morphine Induced Pruritus after Caesarean Section", 《J. OBSTET. GYNAECOL. RES.》, vol. 25, no. 3, 31 December 1999 (1999-12-31), pages 209 - 213, XP055262656, DOI: 10.1111/j.1447-0756.1999.tb01149.x *
CHIA-CHIH LIAO等: "Efficacy of Intramuscular Nalbuphine versus Diphenhydramine for the Prevention of Epidural Morphine-induced Pruritus after Cesarean Delivery", 《CHANG GUNG MEDICAL JOURNAL》, vol. 34, 31 December 2011 (2011-12-31), pages 172 - 178 *

Also Published As

Publication number Publication date
HK1215541A1 (en) 2016-09-02
ZA201906339B (en) 2021-07-28
AU2013359017B2 (en) 2018-05-10
CA2892393C (en) 2021-06-08
MX2015007518A (es) 2016-03-01
JP7072280B2 (ja) 2022-05-20
NZ708371A (en) 2020-05-29
AU2018214098A1 (en) 2018-08-30
KR20210050585A (ko) 2021-05-07
JP6823857B2 (ja) 2021-02-03
RU2015128265A (ru) 2017-01-25
AU2018214098B2 (en) 2019-04-18
JP2021020947A (ja) 2021-02-18
WO2014093871A1 (en) 2014-06-19
CN104981246A (zh) 2015-10-14
ZA201504229B (en) 2021-07-28
JP2016506398A (ja) 2016-03-03
EP2931279B1 (en) 2024-03-20
JP2019131588A (ja) 2019-08-08
KR20220044385A (ko) 2022-04-07
BR112015013984A2 (pt) 2017-07-11
CA2892393A1 (en) 2014-06-19
AU2013359017A1 (en) 2015-06-11
ES2984559T3 (es) 2024-10-29
EP2931279A4 (en) 2016-05-11
KR20150093702A (ko) 2015-08-18
JP2022105095A (ja) 2022-07-12
EP2931279A1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
JP7072280B2 (ja) 抗そう痒剤
US20250032480A1 (en) Methods for treating pruritus
US8987289B2 (en) Methods for treating pruritus
US20190099416A1 (en) Methods for treating pruritus
US8637538B1 (en) Methods for treatment of pruritis
US20170216277A1 (en) Therapeutic use of nalbuphine without aquaretic effects
EP3432871B1 (en) Treatment of uremic pruritus
HK40013011A (en) Methods for treating pruritus
HK1215541B (en) Methods for treating pruritus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013011

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191220

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40013011

Country of ref document: HK